LXRXLexicon Pharmaceuticals, Inc.
$1.67+40% 1Y
$1.67
$1.1452 weeks$2.50
LXRX in its own filings
LXRX's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
476
Events found in the filings · across 1,402 filings · the record starts in 2000
- Hard flags
- 1
Hard flags
- Most recent filing
- Aug 6, 2026
Most recent filing · Form 10-Q
- Record starts
- May 5, 2000
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 5, 2026
- Delisting notice / listing-rule failure2 occurrences
- 2025-01-07
- SEC comment-letter activity50 occurrences
- 2024-08-09
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- May 6, 2026Loan and Security Agreement On May 4, 2026, Lexicon Pharmaceuticals, Inc. (“Lexicon”) and its subsidiaries entered into a loan and security agreement with Hercules Capital, Inc. and certain of its affiliates (“Hercules”) that provides up to $100 million in borrowing capacity (the “Hercules Term Loans”) available in …Material agreement entered · Form 8-K
- Apr 30, 2026Unregistered Sale of Equity Securities On April 30, 2026, each outstanding share of our Series B Convertible Preferred Stock, par value $0.01 per share (the “Preferred Stock”), was converted (the “conversion”) into 50 shares of our common stock, par value $0.001 per share (the “Common Stock”). 408,434.7 shares of …Material agreement entered · Form 8-K
- Feb 2, 2026Underwriting Agreement On January 29, 2026, Lexicon Pharmaceuticals, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Jefferies LLC (“Jefferies”) and Piper Sandler & Co. (“Piper Sandler”), as representatives of the several underwriters named therein (the “Underwriters”) …Material agreement entered · Form 8-K
- Jan 29, 2026The information set forth in.Earnings release · Form 8-K
- Nov 10, 2025On November 6, 2025, Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “Company”), in connection with its previously announced Open Market Sale Agreement SM, dated December 29, 2023 (the “Agreement”), with Jefferies LLC, as sales agent, pursuant to which the Company may offer and sell, from time to time …Other event · Form 8-K
- Nov 6, 2025On November 6, 2025, Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “Company”), in connection with its previously announced Open Market Sale Agreement SM, dated December 29, 2023 (the “Agreement”), with Jefferies LLC, as sales agent, pursuant to which the Company may offer and sell, from time to time …Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…